Literature DB >> 856236

Assessment of response to therapy in advanced breast cancer.

J L Hayward, P P Carbone, J C Heusen, S Kumaoka, A Segaloff, R D Rubens.   

Abstract

A system is proposed by the UICC for assessing response to treatment of advanced breast cancers.

Entities:  

Mesh：

Year:  1977        PMID： 856236      PMCID： PMC2025288          DOI： 10.1038/bjc.1977.42

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  96 in total

1.  Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.

Authors:  P E Lønning; M Dowsett; A Jones; D Ekse; S Jacobs; F McNeil; D C Johannessen; T J Powles
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

3.  DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.

Authors:  Xi-Ru Li; Liu-Quan Cheng; Mei Liu; Yan-Jun Zhang; Jian-Dong Wang; Ai-Lian Zhang; Xin Song; Jie Li; Yi-Qiong Zheng; Lei Liu
Journal:  Med Oncol       Date:  2011-02-01       Impact factor: 3.064

4.  ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Xi-ru Li; Mei Liu; Yan-jun Zhang; Jian-dong Wang; Yi-qiong Zheng; Jie Li; Bing Ma; Xin Song
Journal:  Med Oncol       Date:  2010-09-25       Impact factor: 3.064

Review 5.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer.

Authors:  F A Holmes; L Esparza; H Y Yap; A U Buzdar; G R Blumenschein; G N Hortobagyi
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Management of brain metastases from breast cancer by combination chemotherapy.

Authors:  D Rosner; T Nemoto; J Pickren; W Lane
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

8.  Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria.

Authors:  V Vassiliou; D Andreopoulos
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

9.  Molecular alterations in key-regulator genes among patients with T4 breast carcinoma.

Authors:  Bruno Massidda; Mariacristina Sini; Mario Budroni; Francesco Atzori; Mariacristina Deidda; Valeria Pusceddu; Mariateresa Perra; Paola Sirigu; Antonio Cossu; Grazia Palomba; Mariateresa Ionta; Giuseppe Palmieri
Journal:  BMC Cancer       Date:  2010-08-24       Impact factor: 4.430

10.  Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.

Authors:  T Hamaoka; C M Costelloe; J E Madewell; P Liu; D A Berry; R Islam; R L Theriault; G N Hortobagyi; N T Ueno
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.